(A) Scheme of using Fe-TBP MOFs to overcome hypoxia for PDT-primed cancer immunotherapy. (B) Time-dependent oxygen generation. (C) Tumor growth curves of CT26 tumor-bearing mice with T-cell or B-cell depletion. (D) Scheme of the core-satellite MOF-UCNPs assemblies and the mixture of the MOF-UCNPs. (E) Singlet-oxygen production from the MOF-UCNPs with different ratios.
MOF: Metal-organic framework; NIR: Near infrared; PDT: Photodynamic therapy; TBP: 5,10,15,20-tetra(p-benzoato)porphyrin; UCNP: Upconversion nanoparticle.
(A) Reproduced with permission from [103] © American Chemical Society (2018).
(B) Reproduced with permission from [103] © American Chemical Society (2018).
(C) Reproduced with permission from [103] © American Chemical Society (2018).
(D) Reproduced with permission from [109] © WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim (2017).
(E) Reproduced with permission from [109] © WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim (2017).